Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Eli Lilly and Company
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06238479CT.gov A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Renal Pelvis Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ly4101174 (this asset) | Eli Lilly and Company | P1 | CC · 43 |
| Cis-Diamminedichloroplatinum Ii | H. Lee Moffitt Cancer Center and Research Institute | P3 | BB |
| Vinflunine | Dr Anders Ullén | P2 | BB |
| Pembrolizumab | Alliance for Clinical Trials in Oncology | P3 | B |
| Icrucumab | Eli Lilly and Company | P2 | B |
| Carboplatin | Dr Anders Ullén | P2 | B |
| Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer | Eli Lilly and Company | P2 | B |
| Docetaxel | Eli Lilly and Company | P2 | B |
| Tivozanib | Alliance for Clinical Trials in Oncology | P3 | B |
+9 more in the Renal Pelvis Carcinoma cohort
Other indications for ly4101174
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Urinary Bladder Neoplasm | — | P1 | CC · 43 |
| Cancer | — | P1 | CC · 43 |
| Urinary Bladder Carcinoma | — | P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ly4101174 in Renal Pelvis Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ly4101174-renal-pelvis-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →